Editorial Staff

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

/in , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute’s Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.

Guest:

Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Guest Host:

Dr. William S. Smith is Pioneer’s Visiting Fellow in the Life Sciences. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor’s office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer’s corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.

Get new episodes of Hubwonk in your inbox!

Recent episodes:

Republicans at a Crossroads: Weighing the Boost and Baggage of the Trump Train

This week on Hubwonk, host Joe Selvaggi talks with political scientist and author, Northeastern University Professor William Mayer, about the new book he has edited, The Elephant in the Room: Donald Trump and the Future of the Republican Party. They discuss how former president Trump has changed, and has been changed, by the GOP, and which path the Republican party is likely to take in the future.

Supreme Judicial Preview: Court Poised To Face Controversy

This week on Hubwonk, host Joe Selvaggi talks with constitutional scholar Thomas Berry about the important questions being decided in the more high profile cases facing the newly opened session of the Supreme Court. They discuss how the addition of newly appointed Justice Ketanji Brown Jackson could add a fresh perspective on the concept of originalism.

Income Inequality Explored: Wage Gap Overlooks Government Intervention

This week on Hubwonk, host Joe Selvaggi talks with John F. Early, economist and author of the newly released book, The Myth of American Inequality, about the history of income inequality, its true size, and trends. They also discuss how census data used in policy decision-making misses nearly all the effects of government intervention and distorts the truth about the income American families actually have to spend.

Collegiate Kangaroo Courts: Title IX Rewrite Expels Free Expression and Due Process

This week on Hubwonk, host Joe Selvaggi talks with Pacific Legal Foundation Senior Fellow Alison Somin about the Biden Administration’s proposed modifications to Title IX fair treatment guidelines, challenging principles of free speech and due process, and potentially chilling the culture of free debate in American universities.

Train Wreck Averted: Labor Ties American Economy to the Tracks

This week on Hubwonk, host Joe Selvaggi talks with Dominic Pino, Thomas L. Rhodes Fellow at the National Review Institute, about his research and writing on the recently averted rail strike, including how the rail industry is organized, what labor’s demands were, and how the prospect of a nationwide rail strike exposed vulnerabilities within the American economy.

Gargantuan Graduation Gift: Biden Writes Check From Taxpayers To College Grads

This week on Hubwonk, host Joe Selvaggi talks with Dr. Beth Akers, AEI Senior Fellow, about the recent presidential executive order to cancel an estimated $500 billion in outstanding student debt. They explore who benefits, who pays, and the likely effects on tuition and the borrowing habits of future students.

MBTA’s Runaway Crisis: Legacy of Neglect Demands Comprehensive Reform

This week on Hubwonk, host Joe Selvaggi talks with Andrew Bagley, Vice President for Policy and Research at Massachusetts Taxpayers Foundation, about their recent report entitled, The MBTA Crisis is Complicated - Fixing It Will Be Too, diving into the details on why the T is in crisis and what the public must demand of policy makers to get it back on track.

The Taxman Cometh: Who Will Pay When the Newly Funded IRS Knocks?

This week on Hubwonk, host Joe Selvaggi talks with Heritage Foundation senior research fellow Rachel Greszler about the $80 billion investment in the Internal Revenue Service, focusing on the promise to limit enhanced enforcement to high earners and whether the IRS will likely need to expand its net.

Civil Society’s Stockade: Protecting Pluralism From Progressive Puritanism

This week on Hubwonk, host Joe Selvaggi talks with Noah Rothman, associate editor of Commentary magazine, about his recently released book, "The Rise of the New Puritans: Fighting Back Against Progressives' War On Fun," examining how the attempt to remoralize American culture mirrors similar social movements in the past and what concerned onlookers can do to better manage this frenzied phenomenon.

Drug Price Control: Bad Medicine for Healthcare and Region

Hubwonk host Joe Selvaggi talks with Dr. Bill Smith, Director of Pioneer Institute’s Life Sciences Initiative, about the impact of the Inflation Reduction Act on long-term health costs. They discuss the bill's unintended consequences, potential effect on the region’s vibrant pharmaceutical research and development sector, and what citizens can do about it.